﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>12</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2022</Year>
        <Month>05</Month>
        <DAY>21</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties</ArticleTitle>
    <FirstPage>603</FirstPage>
    <LastPage>612</LastPage>
    <ELocationID EIdType="doi">10.34172/apb.2022.063</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Rohmad Yudi</FirstName>
        <LastName>Utomo</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-4803-9417</Identifier>
      </Author>
      <Author>
        <FirstName>Febri</FirstName>
        <LastName>Wulandari</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0638-8240</Identifier>
      </Author>
      <Author>
        <FirstName>Dhania</FirstName>
        <LastName>Novitasari</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-5661-8841</Identifier>
      </Author>
      <Author>
        <FirstName>Beni</FirstName>
        <LastName>Lestari</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-5658-0572</Identifier>
      </Author>
      <Author>
        <FirstName>Ratna Asmah</FirstName>
        <LastName>Susidarti</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0973-441X</Identifier>
      </Author>
      <Author>
        <FirstName>Riris Istighfari</FirstName>
        <LastName>Jenie</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0230-6260</Identifier>
      </Author>
      <Author>
        <FirstName>Jun-ya</FirstName>
        <LastName>Kato</LastName>
      </Author>
      <Author>
        <FirstName>Sardjiman</FirstName>
        <LastName>Sardjiman</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-5398-4109</Identifier>
      </Author>
      <Author>
        <FirstName>Edy</FirstName>
        <LastName>Meiyanto</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0886-6322</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/apb.2022.063</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2020</Year>
        <Month>05</Month>
        <Day>04</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2021</Year>
        <Month>07</Month>
        <Day>02</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: This study aimed to challenge the anticancer potency of pentagamavunone-1 (PGV-1) and obtain a new compound (Chemoprevention-Curcumin Analog 1.1, CCA-1.1) withimproved chemical and pharmacological properties.Methods: CCA-1.1 was prepared by changing the ketone group of PGV-1 into a hydroxylgroup with NaBH4 as the reducing agent. The product was purified under preparative layerchromatography and confirmed with HPLC to show about 93% purity. It was tested for itssolubility, stability, and cytotoxic activities on several cancer cells. The structure of the productwas characterized using 1HNMR, 13C-NMR, FT-IR, and HR-mass spectroscopy.Results: Molecular docking analysis showed that CCA-1.1 performed similar or better interactionto NF-κB pathway-related signaling proteins (HER2, EGFR, IKK, ER-alpha, and ER-beta) andreactive oxygen species (ROS) metabolic enzymes (NQO1, NQO2, GSTP1, AKC1R1, andGLO1) compared with PGV-1, indicating that CCA-1.1 exhibits the same or better anticanceractivity than PGV-1. CCA-1.1 also showed better solubility and stability than PGV-1 in aqueoussolution at pH 1.0–7.4 under light exposure at room temperature. The cytotoxic activities ofCCA-1.1 against several (10) cancer cell lines revealed the same or better potency than PGV-1.Conclusion: In conclusion, CCA-1.1 performs better chemical and anticancer properties thanPGV-1 and shows promise as an anticancer agent with high selectivity.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Curcumin analog</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CCA-1.1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">NF-κB</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Reactive oxygen species</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cytotoxic</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>